Teenagers with type 1 diabetes now have the first randomized trial evidence that an SGLT2 inhibitor can protect their kidneys ...

Patients with chronic kidney disease and type 2 diabetes receiving pharmacist-led outreach were nearly twice as likely to start an SGLT2 inhibitor as those receiving usual care.

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...

Photo courtesy of Shutterstock According to medical experts, Type 2 diabetes is one of the fastest-growing health problems ...

A diabetes drug was linked to a surprising effect on the risk of dementia.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...